Cellectis (CLLS) Shareholder's Equity Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.77% |
| Dec 31, 2025 | -15.53% |
| Sep 30, 2025 | -11.63% |
| Jun 30, 2025 | -18.67% |
| Mar 31, 2025 | -16.98% |
| Dec 31, 2024 | -17.86% |
| Sep 30, 2024 | -20.96% |
| Jun 30, 2024 | -21.08% |
| Mar 31, 2024 | -32.13% |
| Dec 31, 2023 | -35.03% |
| Sep 30, 2023 | -38.43% |
| Jun 30, 2023 | -34.59% |
| Mar 31, 2023 | -31.24% |
| Dec 31, 2022 | -26.34% |
| Sep 30, 2022 | -27.48% |
| Jun 30, 2022 | -23.62% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -16.71% |
| Sep 30, 2021 | -17.76% |
| Jun 30, 2021 | -14.80% |
| Mar 31, 2021 | 1.54% |
| Dec 31, 2020 | 127.01% |
| Sep 30, 2020 | 2.82% |
| Jun 30, 2020 | 9.77% |
| Mar 31, 2020 | 11.06% |
| Dec 31, 2019 | 3.85% |
| Sep 30, 2019 | 10.27% |
| Jun 30, 2019 | 11.88% |
| Mar 31, 2019 | 16.81% |
| Dec 31, 2018 | 12.31% |
| Sep 30, 2018 | 20.94% |
| Jun 30, 2018 | 22.06% |
| Mar 31, 2018 | -2.08% |
| Dec 31, 2017 | -29.20% |